COMMUNIQUÉS West-GlobeNewswire

-
Thesecondopinion Celebrates 50 Years of Empowering the Cancer Community
03/10/2019 -
Obalon Announces Repayment of All Long-Term Debt and Regaining of Compliance with NASDAQ Listing Requirement
03/10/2019 -
Golden Leaf Holdings Ltd. Announces Termination of Employment of President of Medical Marijuana Group Consulting Ltd. and Medical Marihuana Group Corporation
03/10/2019 -
Marrone Bio Innovations to Attend the MicroCap Rodeo Investment Conference in Austin
03/10/2019 -
PDS Biotechnology Corp. Announces Clinical Collaboration with Merck
03/10/2019 -
American Cannabis Company, Inc. Strengthens Team By Adding New VP of Sales & Marketing
03/10/2019 -
Tetra Bio-Pharma Provides Regulatory Update for Its CAUMZ(TM) Kit
03/10/2019 -
Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis
03/10/2019 -
Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
03/10/2019 -
Parexel Appoints John Bell Executive Vice President and Chief Quality Officer
03/10/2019 -
New 48-Week Data Presented at IDWeek Show Trogarzo® Remains Safe and Effective
03/10/2019 -
De nouvelles données de 48 semaines démontrent que Trogarzo(MD) demeure efficace et sécuritaire
03/10/2019 -
REPEAT - AgraFlora Organics Prepares for October 17th Health Canada Regulations with Vertically Integrated Edibles Infrastructure, To Commercialize High-CBD Varietals Under R&D License
03/10/2019 -
AgraFlora Organics se prépare pour les nouvelles réglementations de Santé Canada du 17 octobre avec son usine de produits comestibles verticalement intégrée en vue de commercialiser des produits à forte teneur en CBD sur réception de sa licence de R & D
03/10/2019 -
ORYZON Presents New Positive REIMAGINE Efficacy Data of Vafidemstat in the Treatment of Aggression
03/10/2019 -
Catalyst Biosciences Provides DalcA Phase 2b Trial Update
03/10/2019 -
Spero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial
03/10/2019 -
Albireo Recognizes PFIC Awareness Day and Highlights Urgent Needs of Progressive Familial Intrahepatic Cholestasis Families
03/10/2019 -
Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg
03/10/2019
Pages